As of Friday close, Organon & Co.’s (NYSE:OGN) stock was down -$0.32, moving down -1.72 percent to $18.26. The average number of shares traded per day over the past five days has been 2,418,600 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.28 fall in that time frame. In the last twenty days, the average volume was 2,327,575, while in the previous 50 days, it was 2,223,020.
Since last month, OGN stock retreated -16.70%. Shares of the company fell to $18.22 on 09/22/23, the lowest level in the past month. A 52-week high of $32.43 was reached on 01/18/23 after having rallying from a 52-week low of $18.57. Since the beginning of this year, OGN’s stock price has dropped by -34.62% or -$9.67, and marked a new high 10 times. However, the stock has declined by -43.69% since its 52-week high.
Valuation Metrics
Right now, Organon & Co. (OGN) has a P/E ratio of about 6.19. The stock’s beta is 0.83.
The latest dividend of $0.28 per share was paid out, remained unchanged from last year’s $0.28.
Financial Health
In the three months ended June 29, Organon & Co.’s quick ratio stood at 1.20, while its current ratio was 1.70, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 61.70% percent. In the year ended June 29, EBITDA margin amounted to 31.28%, whereas operating margins totaled 14.30%. Based on annual data, OGN earned $3.88 billion in gross profit and brought in $6.17 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 11.40%. Return on equity (ROE) for the past 12 months was -92.80%.
In Organon & Co.’s quarter-end financial report for June 29, it reported total debt of $8.72 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. OGN’s revenue rose 1.43% to $1.54 billion during the quarter, while net income inched up to $1.61 billion. While analysts expected Organon & Co. to report $1.01 quarterly earnings, the actual figure was $1.31 per share, beating the consensus estimate by 29.70%. During the quarter, the company generated $446.0 million in EBITDA. The liabilities of Organon & Co. were 11.53 billion at the end of its most recent quarter ended June 29, and its total debt was $8.73 billion. The value of shareholders’ equity is $255.57 million.
Technical Picture
This quick technical analysis looks at Organon & Co.’s (OGN) price momentum. With a historical volatility rate of 20.67%, the RSI 9-day stood at 21.06% on 22 September.
With respect to its five-day moving average, the current Organon & Co. price is down by -6.55% percent or -$1.28. At present, OGN shares trade -15.50% below its 20-day simple moving average and -25.47% percent below its 100-day simple moving average. However, the stock is currently trading approximately -11.83% below its SMA50 and -30.70% below its SMA200.
Stochastic coefficient K was 0.71% and Stochastic coefficient D was 1.59%, while ATR was 0.49. Given the Stochastic reading of 1.04% for the 14-day period, the RSI (14) reading has been calculated as 26.72%. As of today, the MACD Oscillator reading stands at -0.55, while the 14-day reading stands at -0.81.
Analyst Ratings
Barclays launched its rating on Organon & Co. (NYSE: OGN) to an Overweight in a note to investors on September 21, 2023. Organon & Co. (OGN) has been rated Overweight by analysts. According to 0 brokerage firms, OGN is a sell, and 3 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 2 analysts rate Organon & Co. stock as buy, with 3 recommending it as overweight.
With a median target price of $27.50, the current consensus forecast for the stock is $23.00 – $43.00. Based on these forecasts, analysts predict Organon & Co. (OGN) will achieve an average price target of $29.75.
